(Q87041760)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26746397%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26746397%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

English

0 references

publication date

1 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26746397%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26746397%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

76113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26746397%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

S50-99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26746397%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ki.2009.192

4 March 2020

exact match

0 references

cites work

Meta-analysis: vitamin D compounds in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Vitamin D levels and early mortality among incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Increased risk of hip fracture among patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Low dose calcitriol versus placebo in patients with predialysis chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Relationship between age, renal function and bone mineral density in the US population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Racial differences in bone mineral density and bone loss among end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

FRAX and the assessment of fracture probability in men and women from the UK

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Vascular calcification mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Differential effects of vitamin D receptor activators on vascular calcification in uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Phosphate restriction in diet therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Phosphorus balance and mineral metabolism with 3 h daily hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Serum phosphate levels and mortality risk among people with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Mild hyperphosphatemia and mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The role of phosphate and other factors on the pathogenesis of renal osteodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Role of vitamin D deficiency in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Vascular calcification: in vitro evidence for the role of inorganic phosphate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Relationship of phosphorus and calcium-phosphorus product with mortality in CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effect of phosphate on parathyroid hormone secretion in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Phosphate regulation of vascular smooth muscle cell calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Review of dialysate calcium concentration in hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Calcium balance during hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Calcium kinetics and the long-term effects of lowering dialysate calcium concentration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Calcium exposure and removal in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Blood pressure response to changes in serum ionized calcium during hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Evidence for abnormal calcium homeostasis in patients with adynamic bone disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Intestinal absorption of aluminium in renal failure.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Differential effects of Vitamin D analogs on bone formation and resorption

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Differential effects of vitamin D analogs on vascular calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Clinical lessons from the calcium-sensing receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Molecular basis of parathyroid hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Calcium/vitamin D supplementation and cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Mortality risk among hemodialysis patients receiving different vitamin D analogs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Vitamin D deficiency and associated factors in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

New vitamin D analogs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Parathyroidectomy: whom and when?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Results of surgical treatment of renal hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Survival following parathyroidectomy among United States dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Survival after Parathyroidectomy in Patients with End-stage Renal Disease and Severe Hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Theoretical implications of the biomechanical fracture threshold

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Assessment of bone quality, quantity, and turnover with multiple methodologies at multiple skeletal sites

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Renal osteodystrophy, phosphate homeostasis, and vascular calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients--retrospective analysis of 1429 iliac crest biopsies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Estrogen therapy and coronary-artery calcification.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Serum gonadotropin and testosterone levels in uremic males undergoing intermittent dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network after menopause and the protective effect of estradiol

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Progression of coronary artery calcification in patients taking alendronate for osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Human parathyroid peptide treatment of vertebral osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

The effect of raloxifene treatment in postmenopausal women with CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021

Growth in renal failure: a longitudinal study of emotional and behavioural changes during trials of growth hormone treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.192

7 January 2021